pharma · Major Depressive Disorder · Primary Erythromelalgia · XENE
Xenon Pharmaceuticals
Xenon Pharmaceuticals is a pharma organization headquartered in Burnaby, CA. It trades on NYSE under ticker XENE. Primary therapeutic focus areas include Major Depressive Disorder, Primary Erythromelalgia, Bipolar Depres
3650 Gilmore Way, Burnaby, BC V5G 4W8, CA HQ
397 Employees
Public company Type
XENE · NYSE Ticker
Company details
- Status
- Public
- HQ
- 3650 Gilmore Way, Burnaby, BC V5G 4W8, CA
- Employees
- 397
- Programs
- 22
- Drugs
- 2
- Patents
- 106
XPF-002
Phase 2 · small molecule · Postherpetic Neuralgia
XPF-002 for Postherpetic Neuralgia is a Phase 2 program (small_molecule) at Xenon Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code XPF-002-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Xenon Pharmaceuticals
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Postherpetic Neuralgia
- Status
- completed
- Trials
- 1